Targets of Small Interfering RNA Restriction During Human Immunodeficiency Virus Type 1 Replication
Overview
Authors
Affiliations
Small interfering RNAs (siRNAs) have been shown to effectively inhibit human immunodeficiency virus type 1 (HIV-1) replication in vitro. The mechanism(s) for this inhibition is poorly understood, as siRNAs may interact with multiple HIV-1 RNA species during different steps of the retroviral life cycle. To define susceptible HIV-1 RNA species, siRNAs were first designed to specifically inhibit two divergent primary HIV-1 isolates via env and gag gene targets. A self-inactivating lentiviral vector harboring these target sequences confirmed that siRNA cannot degrade incoming genomic RNA. Disruption of the incoming core structure by rhesus macaque TRIM5alpha did, however, provide siRNA-RNA-induced silencing complex access to HIV-1 genomic RNA and promoted degradation. In the absence of accelerated core disruption, only newly transcribed HIV-1 mRNA in the cytoplasm is sensitive to siRNA degradation. Inhibitors of HIV-1 mRNA nuclear export, such as leptomycin B and camptothecin, blocked siRNA restriction. All HIV-1 RNA regions and transcripts found 5' of the target sequence, including multiply spliced HIV-1 RNA, were degraded by unidirectional 3'-to-5' siRNA amplification and spreading. In contrast, HIV-1 RNA 3' of the target sequence was not susceptible to siRNA. Even in the presence of siRNA, full-length HIV-1 RNA is still encapsidated into newly assembled viruses. These findings suggest that siRNA can target only a relatively "naked" cytoplasmic HIV-1 RNA despite the involvement of viral RNA at nearly every step in the retroviral life cycle. Protection of HIV-1 RNA within the core following virus entry, during encapsidation/virus assembly, or within the nucleus may reflect virus evolution in response to siRNA, TRIM5alpha, or other host restriction factors.
Tebit D, Nickel G, Gibson R, Rodriguez M, Hathaway N, Bain K EBioMedicine. 2024; 100:104965.
PMID: 38215691 PMC: 10827413. DOI: 10.1016/j.ebiom.2023.104965.
CRISPR-Cas13a Inhibits HIV-1 Infection.
Yin L, Zhao F, Sun H, Wang Z, Huang Y, Zhu W Mol Ther Nucleic Acids. 2020; 21:147-155.
PMID: 32585623 PMC: 7321785. DOI: 10.1016/j.omtn.2020.05.030.
Han W, Li Y, Bagaya B, Tian M, Chamanian M, Zhu C J AIDS Immune Res. 2016; 1(1).
PMID: 27239643 PMC: 4882926.
SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness.
Rausch J, Tian M, Li Y, Angelova L, Bagaya B, Krebs K PLoS One. 2015; 10(4):e0122953.
PMID: 25860884 PMC: 4393142. DOI: 10.1371/journal.pone.0122953.
Wheeler L Infect Dis Obstet Gynecol. 2014; 2014:125087.
PMID: 24526828 PMC: 3913465. DOI: 10.1155/2014/125087.